Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Health Catalyst (HCAT) EBITDA Margin (2018 - 2025)

Health Catalyst's EBITDA Margin history spans 8 years, with the latest figure at 109.91% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 9207.0% year-over-year to 109.91%; the TTM value through Dec 2025 reached 46.88%, down 2828.0%, while the annual FY2025 figure was 46.88%, 2828.0% down from the prior year.
  • EBITDA Margin reached 109.91% in Q4 2025 per HCAT's latest filing, down from 17.96% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 13.87% in Q3 2024 to a low of 109.91% in Q4 2025.
  • Average EBITDA Margin over 5 years is 41.62%, with a median of 41.89% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: surged 3338bps in 2023, then tumbled -9207bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 66.08% in 2021, then increased by 27bps to 48.5% in 2022, then increased by 18bps to 39.54% in 2023, then surged by 55bps to 17.84% in 2024, then crashed by -516bps to 109.91% in 2025.
  • Per Business Quant, the three most recent readings for HCAT's EBITDA Margin are 109.91% (Q4 2025), 17.96% (Q3 2025), and 41.49% (Q2 2025).